BTIG raised the firm’s price target on Establishment Labs (ESTA) to $81 from $70 and keeps a Buy rating on the shares. To get a better idea of Motiva adoption trends and market share shifts over the coming years, the firm conducted a brief poll of 33 U.S. plastic surgeons who perform aesthetic breast augmentations in the week following the company’s Q3 earnings call, and the polled surgeons anticipate the market will remain healthy, with procedural volumes expected to increase at a 14% CAGR from 2025-2027, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESTA:
- Establishment Labs price target raised to $70 from $48 at Needham
- Establishment Labs price target raised to $72 from $60 at Canaccord
- Establishment Labs price target raised to $71 from $45 at JPMorgan
- Establishment Labs price target raised to $85 from $70 at Mizuho
- Strong Financial Performance and Positive Outlook Lead to Buy Rating for Establishment Labs Holdings